112088-77-4

Basic information

• Product Name: 6-chloro-9-(4-methoxybenzyl)-9H-purine
• Synonyms: 6-chloro-9-(4-methoxybenzyl)-9H-purine
• CAS NO: 112088-77-4
• Molecular Formula: C₁₃H₁₁ClN₄O
• Molecular Weight: 274.70564
• Mol File: 112088-77-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-9-(4-methoxybenzyl)-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-9-(4-methoxybenzyl)-9H-purine(112088-77-4)
• EPA Substance Registry System: 6-chloro-9-(4-methoxybenzyl)-9H-purine(112088-77-4)

Safety Data

• Hazardous Substances Data: 112088-77-4(Hazardous Substances Data)

Usage

Chemical compound

6-chloro-9-(4-methoxybenzyl)-9H-purine

Family

Purine

Type

Purine analog and kinase inhibitor

Therapeutic potential

Treatment of cancer and viral infections

Mechanism of action

Blocks growth and proliferation of cancer cells by inhibiting signaling pathways

Antiviral activity

Demonstrated against certain viruses

Current status

Under investigation for potential uses, further research needed

Upstream product

• 87-42-3 6-chloro-7H-purine 
• 824-94-2 p-methoxybenzyl chloride 
• 87-42-3 6-chloropurine 
• 2746-25-0 p-Methoxybenzyl bromide 

Downstream Products

• 1125-39-9 1-Methylhypoxanthine 

Relevant articles and documents

OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy

6-Thiopurine (6TP) is a currently prescribed drug in the treatment of diseases ranging from Crohn's disease to acute lymphocytic leukemia. While its potent mode of action is through incorporation into DNA as a thiol mimic of deoxyguanosine, severe toxicit

OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Chemical synthesis and enzymatic properties of RNase A analogues designed to enhance second-step catalytic activity

In this paper, we have used total chemical synthesis of RNase A analogues in order to probe the molecular basis of enzyme catalysis. Our goal was to obligately fill the adenine-binding pocket on the enzyme molecule, and to thus pre-orient the imidazole side chain of His119 in its catalytically productive orientation. Two designed analogues of the RNase A protein molecule that contained an adenine moiety covalently bound to distinct amino acid side chains adjacent to the adenine binding pocket were prepared. A crystal structure of one analogue was determined at 2.3 ? resolution. Kinetic data for RNA transphosporylation and 2′,3′ cyclic mononucleotide hydrolysis were acquired for the adenine-containing RNase A analogue proteins. As anticipated, the presence of a covalently attached adenine on the enzyme molecule decreased the rate of transphosphorylation and increased the rate of hydrolysis, although the magnitude of the effects was small. This work illustrates the use of total protein synthesis to investigate the chemistry of enzyme catalysis in ways not possible through traditional biochemistry or molecular biology.

Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines

9-Aryl-, 9-arylsulfonyl- and 9-benzyl-6-(2-furyl)purines were synthesized by N-alkylation or N-arylation of the purine followed by Stille coupling to introduce the furyl substituent in the 6-position and the compounds screened for activity against Mycobac

6-(Alkylamino)-9-benzyl-9H-purines. A New Class of Anticonvulsant Agents

Several 9-alkyl-6-substituted-purines were synthesized and tested for anticonvulsant activity against maximal electroshock-induced seizures (MES) in rats.Most compounds were prepared in three steps from 5-amino-4,6-dichloropyrimidine or in two steps via alkylation of 6-chloropurine.Potent anticonvulsant activity against MES resided in compounds that contain a benzyl substituent at the 9-position of 6-(methylamino)- or 6-(dimethylamino)purine.Among commonly used agents for control of seizures, this type of structure represents a new class of potent anticonvulsant agents.